advanc
stage
cancer
difficult
control
use
convent
therapi
chemotherapi
surgeri
radiat
therefor
new
innov
therapi
urgent
requir
order
combat
high
mortal
morbid
associ
cancer
antigenspecif
immunotherapi
emerg
attract
approach
treatment
cancer
sinc
abil
specif
erad
system
tumor
control
metastas
without
damag
normal
cell
dna
vaccin
becom
potenti
promis
approach
antigenspecif
immunotherapi
due
safeti
stabil
eas
prepar
review
see
previous
develop
sever
innov
strategi
enhanc
dna
vaccin
potenc
directli
target
dna
dendrit
cell
dc
vivo
via
gene
gun
well
modifi
properti
antigenexpress
dc
review
see
one
strategi
enhanc
dna
vaccin
potenc
use
intracellular
target
strategi
enhanc
mhc
class
iii
antigen
present
process
dc
previous
studi
linkag
calreticulin
crt
protein
locat
endoplasm
reticulum
er
review
see
sever
antigen
includ
human
papillomaviru
nucleocapsid
protein
sever
acut
respiratori
syndrom
sar
coronaviru
intraderm
administr
crt
link
target
antigen
led
signific
increas
antigenspecif
cell
immun
respons
impress
antitumor
effect
thu
crt
shown
highli
potent
enhanc
antigenspecif
immun
respons
antitumor
effect
gener
dna
vaccin
sever
preclin
model
anoth
novel
cancer
therapi
involv
employ
vascular
disrupt
agent
acid
dmxaa
vascular
disrupt
agent
new
class
potenti
anticanc
drug
select
destroy
establish
tumor
vasculatur
shutdown
blood
suppli
solid
tumor
caus
extens
tumor
cell
necrosi
review
see
dmxaa
synthet
flavonoid
induc
product
local
cytokin
includ
dmxaa
shown
induc
antitumor
effect
anim
model
especi
combin
establish
anticanc
agent
demonstr
good
safeti
profil
shown
promis
phase
clinic
trial
current
studi
aim
test
combin
dmxaa
treatment
dna
vaccin
enhanc
antitumor
effect
cell
immun
respons
treat
mice
also
aim
explor
appropri
regimen
mechan
action
drug
clinic
implic
current
studi
discuss
mice
purchas
nation
cancer
institut
frederick
md
weekold
induc
nitric
oxid
synthas
defici
ino
wildtyp
control
mice
purchas
jackson
laboratori
bar
harbor
week
old
wildtyp
control
mice
purchas
tacon
hudson
ny
anim
maintain
specificpathogen
free
condit
procedur
perform
accord
approv
protocol
accord
recommend
proper
use
care
laboratori
anim
restrict
peptid
ydfafrdl
restrict
peptid
rahynivtf
synthes
macromolecular
resourc
denver
co
puriti
fitcconjug
rat
antimous
peconjug
antimous
antibodi
purchas
bd
pharmingen
bd
pharmingen
san
diego
ca
acid
dmxaa
purchas
sigma
st
loui
mo
dmxaa
dissolv
sodium
bicarbon
inject
intraperiton
ip
dose
mgkg
bodi
weight
tumor
cell
gener
previous
describ
grown
rpmi
medium
contain
fetal
bovin
serum
mm
glutamin
mm
sodium
pyruv
iuml
penicillin
streptomycin
nonessenti
amino
acid
mgml
gener
plasmid
plasmid
padreexpress
plasmid
vaccinia
viru
encod
describ
previous
mice
five
per
group
inject
tumor
cell
subcutan
flank
site
pb
tumor
measur
twice
week
tumor
volum
estim
use
formula
largest
diamet
perpendicular
diamet
prepar
dnacoat
gold
particl
gene
gun
particlemedi
dna
vaccin
perform
use
heliumdriven
gene
gun
biorad
laboratori
inc
hercul
ca
accord
protocol
describ
previous
gold
particl
coat
encod
padr
deliv
shave
abdomin
region
mice
use
heliumdriven
gene
gun
discharg
pressur
psi
mice
immun
variou
dna
vaccin
receiv
boost
regimen
indic
figur
legend
vaccinia
encod
vaccin
pfu
virus
inject
intraperiton
volum
splenocyt
harvest
week
last
vaccin
intracellular
cytokin
stain
pool
splenocyt
vaccin
group
incub
hour
peptid
peptid
padr
peptid
presenc
golgiplug
bd
pharmingen
san
diego
ca
stimul
splenocyt
wash
facscan
buffer
stain
peconjug
monoclon
rat
antimous
clone
cell
subject
intracellular
cytokin
stain
use
cytofixcytoperm
kit
accord
manufactur
instruct
bd
pharmingen
san
diego
ca
intracellular
stain
fitcconjug
rat
antimous
flow
cytometri
analysi
perform
use
facscalibur
cellquest
softwar
bd
bioscienc
mountain
view
ca
mice
treat
dmxaa
mgkg
via
ip
inject
hour
later
splenocyt
harvest
apoptosi
cell
analyz
stain
splenocyt
annexin
v
stain
kit
bd
pharmingen
accord
protocol
provid
manufactur
weekold
mice
vaccin
dna
via
gene
gun
deliveri
day
vaccin
mice
treat
either
mgkg
dmxaa
buffer
via
ip
inject
mous
serum
collect
hour
later
store
assay
mous
cytokin
analyz
use
bioplex
pro
mous
cytokin
assay
biorad
accord
manufactur
protocol
sampl
assay
duplic
data
express
mean
standard
deviat
sd
repres
least
two
differ
experi
comparison
individu
data
point
made
student
test
p
valu
less
consid
signific
determin
antitumor
effect
treatment
dmxaa
first
challeng
group
mice
per
group
tumor
cell
treat
singl
dose
dmxaa
administ
day
tumor
challeng
via
ip
inject
monitor
tumor
size
time
shown
figur
tumor
bear
mice
treat
dmxaa
show
significantli
lower
tumor
volum
time
compar
tumor
bear
mice
without
dmxaa
treatment
p
also
character
cell
immun
respons
mice
one
week
dmxaa
treatment
splenocyt
tumorbear
mice
harvest
character
cell
use
intracellular
stain
follow
flow
cytometri
analysi
howev
shown
figur
found
mice
treat
dmxaa
capabl
significantli
enhanc
cell
immun
respons
compar
mice
without
dmxaa
treatment
taken
togeth
data
indic
treatment
dmxaa
gener
signific
therapeut
effect
tumor
enhanc
antigenspecif
immun
respons
tumor
bear
mice
order
determin
therapeut
antitumor
effect
cell
immun
respons
tumorbear
mice
treat
dmxaa
combin
dna
vaccin
first
challeng
group
mice
per
group
tumor
cell
treat
dna
vaccin
without
dmxaa
illustr
figur
seven
day
last
vaccin
harvest
splenocyt
vaccin
mice
character
presenc
cell
use
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
figur
tumorbear
mice
treat
dna
vaccin
combin
dmxaa
gener
best
therapeut
antitumor
effect
compar
mice
treat
regimen
p
furthermor
mice
treat
dna
vaccin
combin
dmxaa
also
gener
highest
number
cell
compar
mice
treat
regimen
thu
result
suggest
treatment
tumorbear
mice
dmxaa
enhanc
system
cell
immun
respons
antitumor
effect
gener
dna
vaccin
order
determin
optim
regimen
enhanc
antigenspecif
cell
immun
respons
gener
dna
vaccin
use
dmxaa
mice
per
group
vaccin
dna
vaccin
three
time
day
interv
via
gene
gun
deliveri
treat
dmxaa
day
first
vaccin
simultan
day
first
vaccin
indic
figur
vaccin
mice
without
dmxaa
treatment
use
control
seven
day
last
vaccin
splenocyt
harvest
vaccin
mice
character
presenc
cell
use
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
figur
vaccin
mice
treat
dmxaa
day
vaccin
gener
best
cell
immun
respons
compar
regimen
furthermor
observ
vaccin
mice
treat
dmxaa
time
vaccin
day
first
vaccin
gener
suppress
cell
immun
respons
compar
vaccin
mice
without
dmxaa
treatment
thu
data
indic
administr
dmxaa
day
first
dna
vaccin
gener
significantli
enhanc
cell
immun
respons
tumorbear
mice
order
determin
observ
phenomenon
also
applic
tumorbear
mice
mice
per
group
challeng
tumor
cell
subcutan
vaccin
dna
vaccin
via
gene
gun
deliveri
treat
dmxaa
either
first
vaccin
first
vaccin
indic
figur
one
week
last
vaccin
splenocyt
tumorbear
mice
harvest
character
cell
use
intracellular
stain
follow
flow
cytometri
analysi
shown
figur
tumorbear
mice
treat
dmxaa
day
first
vaccin
gener
significantli
higher
cell
immun
respons
compar
tumorbear
mice
treat
dmxaa
vaccin
p
also
observ
vaccin
tumorbear
mice
treat
dmxaa
time
vaccin
day
vaccin
gener
suppress
cell
immun
respons
compar
vaccin
mice
without
dmxaa
treatment
furthermor
tumorbear
mice
treat
dmxaa
day
first
vaccin
gener
significantli
increas
number
activ
dendrit
cell
compar
control
addit
treatment
dmxaa
also
led
increas
express
costimulatori
marker
dc
activ
compar
control
see
addit
file
figur
increas
number
function
dc
contribut
enhanc
process
present
antigen
gener
cell
treat
mice
taken
togeth
data
indic
time
administr
dmxaa
significantli
influenc
cell
immun
respons
treat
mice
order
determin
observ
enhanc
hpv
dna
vaccineinduc
antigenspecif
immun
respons
dmxaa
also
applic
antigenspecif
vaccin
mice
per
group
vaccin
dna
vaccinia
viru
padr
dna
vaccin
via
gene
gun
deliveri
treat
dmxaa
day
vaccin
simultan
day
vaccin
indic
figur
one
week
last
vaccin
splenocyt
mice
harvest
character
antigenspecif
cell
immun
respons
use
intracellular
stain
follow
flow
cytometri
analysi
shown
figur
mice
vaccin
differ
vaccin
dna
vaccinia
viru
padr
dna
treat
dmxaa
day
first
vaccin
gener
best
antigenspecif
cell
immun
respons
cell
respons
b
cell
respons
c
padrespecif
cell
immun
respons
compar
regimen
thu
data
indic
administr
dmxaa
three
day
first
vaccin
capabl
enhanc
antigenspecif
immun
respons
differ
vaccin
system
order
determin
addit
dose
dmxaa
follow
first
vaccin
would
enhanc
immun
respons
gener
vaccin
mice
mice
per
group
vaccin
dna
vaccin
via
gene
gun
deliveri
treat
either
one
dose
two
dose
dmxaa
indic
addit
file
figur
one
week
last
vaccin
splenocyt
mice
harvest
character
cell
use
intracellular
stain
follow
flow
cytometri
analysi
shown
addit
file
figur
c
vaccin
mice
treat
two
dose
dmxaa
vaccin
gener
significantli
better
cell
immun
respons
compar
vaccin
mice
treat
one
dose
dmxaa
thu
data
indic
administr
two
dose
dmxaa
first
dna
vaccin
gener
significantli
better
cell
immun
respons
vaccin
mice
compar
administr
one
dose
dmxaa
order
determin
longterm
memori
cell
immun
respons
gener
dna
vaccin
without
treatment
dmxaa
mice
per
group
vaccin
dna
vaccin
three
time
day
interv
via
gene
gun
deliveri
treat
dmxaa
day
vaccin
indic
figur
sixti
day
last
treatment
harvest
splenocyt
vaccin
mice
character
presenc
cell
use
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
figur
vaccin
mice
treat
dmxaa
day
first
vaccin
gener
significantli
better
memori
cell
immun
respons
compar
vaccin
without
dmxaa
treatment
thu
data
indic
administr
dmxaa
day
first
dna
vaccin
enhanc
memori
cell
immun
respons
vaccin
mice
order
determin
coadministr
dmxaa
dna
vaccin
influenc
cytokin
level
serum
mice
observ
immun
enhanc
character
serum
cytokin
concentr
vaccin
mice
treat
dmxaa
day
first
vaccin
see
figur
use
multiplex
analysi
shown
figur
cytokin
gcsf
kc
rant
found
elev
vaccin
mice
treat
dmxaa
compar
vaccin
mice
without
dmxaa
treatment
cytokin
may
potenti
play
role
enhanc
antigenspecif
cell
immun
respons
caus
coadministr
dmxaa
dna
vaccin
order
determin
mechan
dmxaa
lead
suppress
antigenspecif
cell
immun
respons
administ
time
first
dna
vaccin
character
apoptot
cell
death
cell
splenocyt
deriv
mice
treat
dmxaa
mice
per
group
treat
dmxaa
mgkg
via
ip
inject
hour
later
splenocyt
harvest
apoptosi
cell
analyz
annexin
v
stain
signific
differ
level
apoptot
cell
death
cell
among
splenocyt
mice
treat
dmxaa
compar
control
mice
see
addit
file
figur
thu
data
suggest
mechan
dmxaa
lead
suppress
antigenspecif
immun
respons
cell
apoptosi
shown
mice
treat
dmxaa
shown
induc
ino
product
well
tumor
furthermor
ino
implic
play
import
role
antitumor
immun
review
see
thu
order
explor
mechan
action
dmxaa
relat
ino
use
ino
mice
mice
well
wt
mice
per
group
studi
mice
vaccin
dna
vaccin
via
gene
gun
deliveri
treat
dmxaa
either
time
first
vaccin
day
first
vaccin
indic
figur
one
week
last
vaccin
splenocyt
vaccin
mice
harvest
character
cell
use
intracellular
stain
follow
flow
cytometri
analysi
shown
figur
dmxaa
led
suppress
cell
immun
respons
vaccin
wt
mice
administ
dmxaa
suppress
cell
immun
respons
vaccin
ino
mice
indic
ino
major
factor
immunosuppress
mediat
dmxaa
administ
time
first
dna
vaccin
hand
vaccin
mice
treat
dmxaa
administ
suppress
cell
immun
respons
similar
wildtyp
mice
see
figur
also
found
vaccin
ino
mice
mice
treat
dmxaa
led
enhanc
cell
immun
respons
similar
wildtyp
mice
figur
thu
data
indic
ino
contribut
observ
immun
suppress
caus
dmxaa
administr
time
first
dna
vaccin
current
studi
determin
treatment
dmxaa
gener
signific
therapeut
effect
tumor
enhanc
antigenspecif
immun
respons
tumor
bear
mice
found
combin
dmxaa
treatment
therapeut
hpv
dna
vaccin
gener
potent
antitumor
effect
cell
immun
respons
tumor
bear
mice
furthermor
dmxaamedi
enhanc
suppress
cell
immun
respons
gener
dna
vaccin
found
depend
time
administr
dmxaa
also
applic
antigenspecif
vaccin
addit
determin
ino
play
role
immun
suppress
caus
dmxaa
administr
dna
vaccin
data
consist
recent
observ
use
peptidebas
vaccin
cervicovagin
tumor
model
studi
observ
treatment
tumorbear
mice
dmxaa
alon
lead
therapeut
antitumor
effect
without
gener
antigenspecif
immun
respons
figur
may
due
fact
vascular
disrupt
agent
dmxaa
shown
exert
antitumor
effect
non
antigenspecif
mechan
select
destroy
establish
tumor
vasculatur
shut
blood
suppli
solid
tumor
caus
extens
tumor
cell
necrosi
releas
tumor
antigen
caus
dmxaa
treatment
may
suffici
gener
detect
antigenspecif
immun
respons
thu
dmxaa
treatment
alon
tumorbear
mice
fail
lead
appreci
antigenspecif
immun
respons
vaccin
vaccin
lead
increas
number
cell
precursor
tumorbear
mice
may
expand
treatment
dmxaa
result
signific
enhanc
immun
respons
treat
mice
figur
clinic
translat
import
determin
optim
regimen
treatment
dmxaa
studi
show
administr
dmxaa
day
first
dna
vaccin
gener
best
antigenspecif
cell
immun
respons
vaccin
mice
figur
data
also
indic
administr
two
dose
dmxaa
first
dna
vaccin
gener
cell
immun
respons
vaccin
mice
see
addit
file
figur
thu
import
explor
optim
treatment
administr
dmxaa
clinic
trial
studi
explor
mechan
enhanc
induc
dmxaa
found
dmxaa
administ
first
dna
vaccin
influenc
cytokin
profil
serum
mice
observ
immun
enhanc
figur
mice
treat
dmxaaa
first
dna
vaccin
show
upregul
cytokin
gcsf
kc
rant
secret
cell
macrophag
stimul
immun
respons
trauma
lead
inflamm
review
see
gcsf
cytokin
produc
number
differ
tissu
stimul
bone
marrow
produc
granulocyt
stem
cell
kc
rant
chemokin
act
chemoattract
guid
migrat
cell
molecul
believ
play
role
immun
enhanc
gener
dmxaa
administr
additon
data
suggest
treatment
dmxaa
day
first
dna
vaccin
lead
enhanc
antigenspecif
cell
figur
thu
possibl
enhanc
cell
respons
dmxaa
treatment
may
also
contribut
cytokin
well
antigenspecif
cell
data
also
suggest
ino
play
role
immun
suppress
caus
dmxaa
administr
time
first
dna
vaccin
figur
studi
also
show
immun
suppress
mediat
dmxaa
abolish
ino
knockout
mice
dc
essenti
prime
antigenspecif
cell
immun
respons
conceiv
treatment
dmxaa
may
lead
neg
impact
dc
function
presum
mediat
ino
interest
character
role
ino
immunosuppress
mediat
dmxaa
treatment
summari
demonstr
combin
dmxaa
treatment
dna
vaccin
enhanc
suppress
antitumor
effect
cell
immun
respons
treat
mice
depend
time
administr
dmxaa
result
may
potenti
implic
futur
clinic
translat
author
declar
compet
interest
sp
involv
execut
project
involv
interpret
data
write
manuscript
xp
particip
design
studi
statist
analysi
cfh
tcw
provid
overal
supervis
guidanc
project
author
read
approv
manuscript
